GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. - Wikidata - awgldk - TriplyDB

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

http://www.wikidata.org/entity/Q33585286

about

GATA family transcriptional factors: emerging suspects in hematologic disorders Conserved Molecular Underpinnings and Characterization of a Role for Caveolin-1 in the Tumor Microenvironment of Mature T-Cell Lymphomas.Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Lineage-affiliated transcription factors bind the Gata3 Tce1 enhancer to mediate lineage-specific programs.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.HBV suppresses expression of MICA/B on hepatoma cells through up-regulation of transcription factors GATA2 and GATA3 to escape from NK cell surveillance GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.A three-signal model of T-cell lymphoma pathogenesis Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Therapeutic Options for Aggressive T-Cell Lymphomas.Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes.Genetic Landscape and Classification of Peripheral T Cell Lymphomas.2016 WHO Classification update-What's new in lymphoid neoplasms.GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact.T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints.Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Clinicopathological analysis in PTCL-NOS with CADM1 expression.A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.Aspects moléculaires des lymphomes T périphériques (1)Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS

P2860

Q26786487-E4851713-0082-4BB9-B0E1-DB5D8BC12907 Q35840904-A2B83EE5-6F49-4F15-A074-FBC53307AF70 Q36384484-A7DC122F-CE3A-429F-A9C4-F5ABC37C68A5 Q36470196-E109F728-0102-424B-A92D-314B12A57C35 Q36618547-3F1B9790-77BA-4D62-85D5-11C2120AD1FC Q36920426-4DCE3EEF-FA0D-4438-86EB-318B5B9408AD Q37636590-453307D0-D362-428D-AE80-4950B0F9D981 Q37662219-D85FADD5-573E-488C-9702-388F7B57161C Q37665549-AE916AB7-4580-44DF-B1BD-CAD8792F35D6 Q38289038-9D8C59A3-7BB5-4791-850E-68691A0E036A Q38593164-2FACEA18-7FFA-4834-B099-E72E0AB83E9B Q38663689-6A67627A-3DD1-451C-8D3F-C9495C4546C4 Q38675843-7E6814AE-724F-4E51-8511-989E2D2E24E8 Q38702312-BA3A2180-DB4F-4D90-BD2C-FD67967140CD Q38782072-04ACABC2-4BD0-4058-8B59-8C3531A613B1 Q38947647-A7C00B9F-2E21-4034-8B07-D27EF1D07CDA Q38992646-8FBF0381-E7B2-4AEC-A9E9-A7E5A26BD81D Q39055861-5C78DBCE-C251-4BAD-8511-AD6458ACC63B Q39063866-BEB44E67-DCFB-425D-8A57-FA623DA0BFB6 Q39092818-397C3126-2F73-4446-9FED-95262233616D Q39183278-0D9FA346-6655-4F2E-B807-6129A9A57181 Q39266295-BBC8A16D-6B84-4CD4-A7E0-7D9B67E9C3E0 Q40086982-7BA7CD9B-0BFD-4BFA-A0F4-133735A5F8A8 Q40476069-7FA699AC-907E-4933-9D40-744EC2920AB0 Q42391583-8219696E-66E6-4B7B-A414-239FD9921E57 Q45069242-4D379AD1-90F0-4366-B5CA-9E0FCE1D2EBD Q46325508-4F546E01-D9D9-4930-B7B7-ECAB0E1A8C06 Q47097471-F5EBF59A-76DE-4797-A616-8C1DA7158969 Q47133172-DAAEE345-67D4-443F-B11B-120F95680A44 Q47757848-1DE60B7E-08CB-4092-A56D-189767F770EA Q47902760-B86D8C72-FE68-4B79-A26C-1D2F70F770B5 Q48034709-3F83A51B-827C-49EA-9D3E-3F06F4F9241D Q48197102-7C038619-340A-4232-8982-F34F44DEBC62 Q48567161-94DA82BE-83BD-42E9-8281-99D80EC83EDF Q49421936-8AE77316-E021-4CFE-8657-10236EFC9FDE Q57216739-7AB4AAD2-108C-4EBE-9E77-2F4EAF5D1DBA Q58759110-5E23021B-6F44-4D45-8CFC-EFBB25A7E54C

P2860

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

http://www.wikidata.org/entity/Q33585286

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

GATA-3 expression identifies a ...... lecular and clinical features.

@ast

GATA-3 expression identifies a ...... lecular and clinical features.

@en

GATA-3 expression identifies a ...... lecular and clinical features.

@nl

type

label

GATA-3 expression identifies a ...... lecular and clinical features.

@ast

GATA-3 expression identifies a ...... lecular and clinical features.

@en

GATA-3 expression identifies a ...... lecular and clinical features.

@nl

prefLabel

GATA-3 expression identifies a ...... lecular and clinical features.

@ast

GATA-3 expression identifies a ...... lecular and clinical features.

@en

GATA-3 expression identifies a ...... lecular and clinical features.

@nl

P1433

Q33585286-CCDEFC48-7AC8-46AA-9B46-61AE0A9B4D5A

P1476

Q33585286-D9509FBC-0EA0-427A-BD22-69DF642724D5

P2093

Q33585286-00FFD7C0-C7EC-43C5-B150-FB46129CE90F

Q33585286-1A353F9F-87CF-49C4-BA6E-727C4C6897A8

Q33585286-1BE34A77-0A6D-4128-9580-11A8B1A0A976

Q33585286-215CF881-3845-4E63-820A-31EE7CEDF2F7

Q33585286-2FBED8D1-E470-443A-93B4-352DAE154DA1

Q33585286-358A65CA-25A1-4058-87E0-67A24D75F8CF

Q33585286-3B0BB927-FD96-4D47-B013-EB26C749C2A8

Q33585286-45F9F432-833B-4167-9A9A-B1B63F9EB5BA

Q33585286-521193BD-0363-47DD-ACC3-934B53DF5FD7

Q33585286-57503DBB-1F76-4CFD-9121-7A66D3F56867

P2860

Q33585286-01882A46-62F4-453C-807B-00451DCCA59B

Q33585286-10730382-22B3-4981-BAE6-681ABBAE1663

Q33585286-16239F90-A8BC-4B26-B8F4-C45AF61F51FE

Q33585286-168FA36C-3D15-4248-A4DA-82DBE7FEFB51

Q33585286-312BB196-C90F-46D3-98C8-49CC5CF454E3

Q33585286-31CCC12F-C7D1-433C-9A74-A5AD6D6D8A22

Q33585286-34DAD54F-5C4B-49D8-AC00-B127B23DAB3F

Q33585286-4257DF7B-3C42-4E5E-8E64-646C776B4DA4

Q33585286-4701CDE0-D1B9-4C13-B235-9946B1FAC640

Q33585286-486EDD88-9146-4AA3-9672-2FE47134FC3D

P304

Q33585286-66CCF228-2142-4BC9-AB64-7656E4B4BBF0

P31

Q33585286-5F5FA014-470E-4474-A57A-8FECD22076E7

P356

Q33585286-283B380D-291F-40D7-BFC8-C1B3EB76456F

P407

Q33585286-E6095916-B6B3-43DA-82EC-D574585DF5ED

P433

Q33585286-0A972A72-A44C-4525-B014-0D9FB90D8987

P478

Q33585286-3C681F9C-7567-443F-8610-EA94AF43EBC8

P50

Q33585286-07503DDF-0BF3-42F1-A53A-A886A431DACD

Q33585286-3C94C7C0-5C1A-4BFB-81FA-C7A3A959356E

Q33585286-F42E4C62-34B9-4375-A16A-06BE3B0939B6

P577

Q33585286-01760D70-8612-4E15-B064-D249AA763845

P5875

Q33585286-E04C5CB4-BD41-47DE-B489-49A669A7D7F2

P698

Q33585286-9C4DEF4F-D6D0-4D3A-B64F-643A87C7A4D7

P932

Q33585286-CC9E56BD-A61C-4335-A403-5F56DE30730F

P356

BLOOD-2013-12-544809

P1433

P1476

GATA-3 expression identifies a ...... lecular and clinical features.

@en

P2093

Alexandra C Hristov

http://www.w3.org/2001/XMLSchema#string

Avery Polk

http://www.w3.org/2001/XMLSchema#string

Dafydd Thomas

http://www.w3.org/2001/XMLSchema#string

David A Wada

http://www.w3.org/2001/XMLSchema#string

Kay Ristow

http://www.w3.org/2001/XMLSchema#string

Linda E Wellik

http://www.w3.org/2001/XMLSchema#string

Mark R Pittelkow

http://www.w3.org/2001/XMLSchema#string

Robert Briski

http://www.w3.org/2001/XMLSchema#string

Ryan A Wilcox

http://www.w3.org/2001/XMLSchema#string

Stephen M Ansell

http://www.w3.org/2001/XMLSchema#string

P2860

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

Aggressive lymphomas

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

GATA-3 is required for early T lineage progenitor development

Inhibition of Th2 differentiation and GATA-3 expression by BCL-6

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

Differentiation of effector CD4 T cell populations (*)

Follicular helper CD4 T cells (TFH)

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

P304

3007-3015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-12-544809

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Nathanael G. Bailey

Andrew L Feldman

P577

2014-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260108429

http://www.w3.org/2001/XMLSchema#string

P698

24497534

http://www.w3.org/2001/XMLSchema#string

P932

4014843

http://www.w3.org/2001/XMLSchema#string